KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $301.3 million.

  • Nektar Therapeutics' Liabilities and Shareholders Equity fell 2.15% to $301.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 26.04%. This contributed to the annual value of $303.9 million for FY2024, which is 23.66% down from last year.
  • Per Nektar Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $301.3 million for Q3 2025, which was up 45.20% from $207.5 million recorded in Q2 2025.
  • Nektar Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $1.5 billion during Q1 2021, with a 5-year trough of $207.5 million in Q2 2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $343.3 million (2024), whereas its average is $364.8 million.
  • Data for Nektar Therapeutics' Liabilities and Shareholders Equity shows a maximum YoY slumped of 45.15% (in 2023) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $1.1 billion in 2021, then tumbled by 36.39% to $710.6 million in 2022, then plummeted by 43.99% to $398.0 million in 2023, then decreased by 23.66% to $303.9 million in 2024, then fell by 2.15% to $301.3 million in 2025.
  • Its Liabilities and Shareholders Equity was $301.3 million in Q3 2025, compared to $207.5 million in Q2 2025 and $256.2 million in Q1 2025.